1. Home
  2. WB vs IMNM Comparison

WB vs IMNM Comparison

Compare WB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weibo Corporation

WB

Weibo Corporation

HOLD

Current Price

$7.78

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.20

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WB
IMNM
Founded
2009
2006
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
WB
IMNM
Price
$7.78
$22.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
10
Target Price
$14.00
$32.80
AVG Volume (30 Days)
947.0K
1.6M
Earning Date
05-28-2026
05-08-2026
Dividend Yield
7.49%
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$8.35
N/A
Revenue Next Year
$1.73
$1,127.34
P/E Ratio
$5.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.09
$8.67
52 Week High
$12.96
$27.65

Technical Indicators

Market Signals
Indicator
WB
IMNM
Relative Strength Index (RSI) 55.60 51.85
Support Level $7.09 $19.28
Resistance Level $10.49 $23.25
Average True Range (ATR) 0.14 1.16
MACD 0.05 -0.11
Stochastic Oscillator 64.23 17.74

Price Performance

Historical Comparison
WB
IMNM

About WB Weibo Corporation

Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: